• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Metabolomic biomarkers of multiple myeloma: A systemati review

by | Jul 11, 2024 | Publications

Biochim Biophys Acta Rev Cancer. 2024 Jul 8:189151. doi: 10.1016/j.bbcan.2024.189151. Online ahead of print. ABSTRACT Multiple myeloma is an incurable malignancy of clonal plasma cells. Various diagnostic methods are used in parallel to accurately determine stage and...

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

by | Jul 11, 2024 | Publications

Blood Cancer J. 2024 Jul 10;14(1):111. doi: 10.1038/s41408-024-01089-5. ABSTRACT Infection is the leading cause of death in multiple myeloma (MM). However, the cellular composition associated with immune dysfunction is not defined. We analyzed immune profiles in the...

Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation

by | Jul 10, 2024 | Publications

JCO Precis Oncol. 2024 Jul;8:e2300613. doi: 10.1200/PO.23.00613. ABSTRACT PURPOSE: Given the high heterogeneity in survival for patients with multiple myeloma, it would be clinically useful to quantitatively predict the individual survival instead of attributing...

Case Report: Cavernous Sinus Syndrome as the Initial Presentation of Multiple Myeloma

by | Jul 10, 2024 | Publications

Front Ophthalmol (Lausanne). 2022 Mar 30;2:849343. doi: 10.3389/fopht.2022.849343. eCollection 2022. ABSTRACT Multiple myeloma (MM) is the second most common hematologic malignancy and most common primary bone malignancy. Ocular manifestations of MM are extremely rare...

Recent Advances in The Definition of the Molecular Alterations Occurring in Multiple Myeloma

by | Jul 10, 2024 | Publications

Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024062. doi: 10.4084/MJHID.2024.062. eCollection 2024. ABSTRACT Multiple myeloma (MM) is a disorder of the monoclonal plasma cells and is the second most common hematologic malignancy. MM initiation and progression are...

Renal impairment in monoclonal gammopathies and multiple myeloma

by | Jul 10, 2024 | Publications

Cas Lek Cesk. 2024;163(3):98-105. ABSTRACT The incidence of monoclonal gammopathy (MG) increases with age. In individuals over 80 years of age, we can diagnose the presence of monoclonal immunoglobulin (MIg) in up to 10 % of cases. Not only malignant diseases such as...
« Older Entries
Next Entries »

Recent Content

  • Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
  • Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes
  • Deep Responses in Smoldering Multiple Myeloma Linked to Improved Outcomes
  • Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702
  • Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
  • Evaluation of anti-CD38 monoclonal antibody-based immunotherapy in multiple myeloma with renal insufficiency: a systematic review and meta-analysis
  • The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
  • FDA Grants OPN-6602 Orphan Drug Destination for Treatment of Patients With Relapsed, Refractory Multiple Myeloma
  • Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT